Merck's Zepatier added to VA formulary

Merck & Co. Inc. (NYSE:MRK) said the U.S. Department of Veterans Affairs added Zepatier grazoprevir/elbasvir ( MK-5172/ MK-8742) to the VA National Formulary. In January, FDA approved Zepatier to treat HCV genotype 1 and 4 infection (see BioCentury Extra, Jan. 28).

Merck said about 180,000 veterans have chronic HCV infection. The VA covers about 15% of the U.S. HCV genotype 1 market. ...